How to buy Kronos Bio stock (Kronos Bio)

Kronos Bio is a biotechnology business based in the US. Kronos Bio shares (KRON) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.96 – a decrease of 2.25% over the previous week. Kronos Bio employs 58 staff and has a trailing 12-month revenue of around $8.4 million.

Our top picks for where to buy Kronos Bio Inc stock

Buy Kronos Bio stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Kronos Bio stock price (NASDAQ: KRON)

Use our graph to track the performance of KRON stocks over time.

Kronos Bio shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$0.96
52-week range	$0.69 - $1.60
50-day moving average more info button	$0.94
200-day moving average more info button	$1.04
Wall St. target price	$2.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.43

Is it a good time to buy Kronos Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kronos Bio price performance over time

Historical closes compared with the close of $0.9281 from 2024-12-19

1 week (2024-12-13)	-5.29%
1 month (2024-11-21)	6.15%
3 months (2024-09-20)	-9.89%
6 months (2024-06-21)	-14.06%

1 year (2023-12-21)	-22.66%
2 years (2022-12-21)	-37.29%
3 years (2021-12-21)	15.24
5 years (2019-12-17)	N/A

Kronos Bio financials

Revenue TTM	$8.4 million
Gross profit TTM	$0
Return on assets TTM	-28.28%
Return on equity TTM	-63%
Profit margin	0%
Book value	$2.70
Market Capitalization more info button	$57.3 million

TTM: trailing 12 months

Kronos Bio share dividends

We're not expecting Kronos Bio to pay a dividend over the next 12 months.

You may also wish to consider:

Have Kronos Bio's shares ever split?

Kronos Bio's shares were split on a 3:2 basis on 2 November 2003 . So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Kronos Bio shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Kronos Bio shares which in turn could have impacted Kronos Bio's share price.

Kronos Bio share price volatility

Over the last 12 months, Kronos Bio's shares have ranged in value from as little as $0.69 up to $1.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kronos Bio's is 1.864. This would suggest that Kronos Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Kronos Bio's beta into context you can compare it against those of similar companies.

• EXACT Sciences Corporation (EXAS.US): 1.272
• Inovio Pharmaceuticals (INO.US): 0.833
• Moderna (MRNA.US): 1.69

Kronos Bio overview

Kronos Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. .

Frequently asked questions

What percentage of Kronos Bio is owned by insiders or institutions?
Currently 26.903% of Kronos Bio shares are held by insiders and 32.673% by institutions. How many people work for Kronos Bio?
Latest data suggests 58 work at Kronos Bio. When does the fiscal year end for Kronos Bio?
Kronos Bio's fiscal year ends in December. Where is Kronos Bio based?
Kronos Bio's address is: 1300 South El Camino Real, San Mateo, CA, United States, 94402 What is Kronos Bio's ISIN number?
Kronos Bio's international securities identification number is: US50107A1043 What is Kronos Bio's CUSIP number?
Kronos Bio's Committee on Uniform Securities Identification Procedures number is: 501052104